doi:10.2337/db07-1824 Yang X, Qiang Q, Li N, Feng P, Wei W, Hlscher C
The development of GLP-1 RA-specific medical nutrition therapy (MNT) protocols, and the active involvement of an RDN in optimizing key dietary recommendations, including ensuring adequate protein intake (based on g/kg body weight rather than percentage of total energy), increasing fiber intake, and reducing saturated fat intake, is important
Written by Taylor Woosley, Staff Writer
The obesity drug pipeline remains robust, with next-generation therapies and novel mechanisms progressing through multiple phases of clinical development
A survey that included more than 8,000 GLP-1 users found that 15% had tried or were currently microdosing the drug
Plenty of generic medication reminders exist, but Pep is purpose-built for GLP-1 users